Why CeriBell, Inc.’s (CBLL) Stock Is Up 7.33%
As of Thursday, June 04, CeriBell, Inc.’s CBLL share price has surged by 7.33%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient’s EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Commentary & Analysis
Why CeriBell, Inc.’s (CBLL) Stock Is Up 6.21%
As of Wednesday, May 13, CeriBell, Inc.’s CBLL share price has surged by 6.21%, which has investors questioning if this is right time to sell.Michael Rose
Why CeriBell, Inc.’s (CBLL) Stock Is Down 7.58%
As of Tuesday, May 12, CeriBell, Inc.’s CBLL share price has dipped by 7.58%, which has investors questioning if this is right time to buy.Jenna Brashear
Why CeriBell, Inc.’s (CBLL) Stock Is Down 11.52%
As of Tuesday, May 12, CeriBell, Inc.’s CBLL share price has dipped by 11.52%, which has investors questioning if this is right time to buy.Omar Beirat
What You Need to Know About CeriBell, Inc.'s Q2 Earnings
CeriBell, Inc.'s fiscal Q2 earnings report was released on Monday, May 11. Let's dive in to see if (CBLL) missed or beat analyst's expectations.Rosalio Madrigal
Financial Summary
| Share Statistics | CBLL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $671.2 | $337.2 | 41% |
|
| Shares Out (Mil) | 37.7 | 41.9 | 42% |
|
| Institutional Ownership | 92.6% | 77.8% | 62% |
|
| Float (Mil) | 26.1 | 34.7 | 33% |
|
| Beta | na | 0.85 | na |
|
| Avg Daily Volume (000s) | 364 | 278 | 54% |
|
| Price Change (52-week) |
18.6% | 58.7% | 60% |
|
| Growth | CBLL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | na | (5.8%) | na |
|
| EPS (5yr) | na | 11.4% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (16.3%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 5 | |
| Current EPS | ($0.458) | ($1.682) | ($1.098) | |
| Month Ago EPS | ($0.458) | ($1.682) | ($1.098) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 2 | 1 | |
| Three Months Ago EPS | ($0.390) | ($1.456) | ($1.006) | |
| Year/Year Chg | (12.6%) | 15.0% | (42.4%) | |
| Financials | CBLL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $95 | $152 | 26% |
|
| Net Income (TTM) (Mil) | ($60) | ($10) | 14% |
|
| EPS (TTM) | ($1.632) | ($0.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($49) | ($2) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($108) | $1 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $21 | $22 | 33% |
|
| Enterprise Value (Q1) (Mil) | $524 | $304 | 35% |
|
| Valuation | CBLL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.76 | 2.80 | 77% |
|
| P/E | na | 31.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | CBLL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 87.7% | 59.1% | 93% |
|
| Net Margin | (63.5%) | (7.3%) | 10% |
|
| ROA | (30.8%) | (13.7%) | 17% |
|
| ROE | (37.5%) | (15.8%) | 18% |
|
| Liabilities to Assets | 20.9% | 44.7% | 13% |
|
| F-Score | 2 | 4 | 7% |
|
CeriBell, Inc. did not pass any screens on 7/31/2026.
